203 related articles for article (PubMed ID: 34680323)
1. Intra-Tumour Genetic Heterogeneity and Prognosis in High-Risk Neuroblastoma.
López-Carrasco A; Berbegall AP; Martín-Vañó S; Blanquer-Maceiras M; Castel V; Navarro S; Noguera R
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680323
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.
Berbegall AP; Bogen D; Pötschger U; Beiske K; Bown N; Combaret V; Defferrari R; Jeison M; Mazzocco K; Varesio L; Vicha A; Ash S; Castel V; Coze C; Ladenstein R; Owens C; Papadakis V; Ruud E; Amann G; Sementa AR; Navarro S; Ambros PF; Noguera R; Ambros IM
Br J Cancer; 2018 May; 118(11):1502-1512. PubMed ID: 29755120
[TBL] [Abstract][Full Text] [Related]
3. Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes.
Fernández-Blanco B; Berbegall AP; Martin-Vañó S; Castel V; Navarro S; Noguera R
Neoplasia; 2021 Jan; 23(1):12-20. PubMed ID: 33190090
[TBL] [Abstract][Full Text] [Related]
4. Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.
Defferrari R; Mazzocco K; Ambros IM; Ambros PF; Bedwell C; Beiske K; Bénard J; Berbegall AP; Bown N; Combaret V; Couturier J; Erminio G; Gambini C; Garaventa A; Gross N; Haupt R; Kohler J; Jeison M; Lunec J; Marques B; Martinsson T; Noguera R; Parodi S; Schleiermacher G; Tweddle DA; Valent A; Van Roy N; Vicha A; Villamon E; Tonini GP
Br J Cancer; 2015 Jan; 112(2):290-5. PubMed ID: 25356804
[TBL] [Abstract][Full Text] [Related]
5. The impact of surgical radicality on outcome in childhood neuroblastoma.
von Schweinitz D; Hero B; Berthold F
Eur J Pediatr Surg; 2002 Dec; 12(6):402-9. PubMed ID: 12548494
[TBL] [Abstract][Full Text] [Related]
6. [Genomic profile in high risk neuroblastoma by comparative genomic hybridization].
Noguera Salvá R; Piqueras Franco M; Ruiz Saurí A; Llombart-Bosch A; Castel Sánchez V; Navarro Fos S
An Pediatr (Barc); 2006 May; 64(5):449-56. PubMed ID: 16756886
[TBL] [Abstract][Full Text] [Related]
7. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.
Lee E; Lee JW; Lee B; Park K; Shim J; Yoo KH; Koo HH; Sung KW; Park WY
BMC Med Genomics; 2020 Nov; 13(1):171. PubMed ID: 33172452
[TBL] [Abstract][Full Text] [Related]
8. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
Berbegall AP; Villamón E; Piqueras M; Tadeo I; Djos A; Ambros PF; Martinsson T; Ambros IM; Cañete A; Castel V; Navarro S; Noguera R
Oncogene; 2016 Mar; 35(11):1423-32. PubMed ID: 26119945
[TBL] [Abstract][Full Text] [Related]
9. Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients.
Amoroso L; Ognibene M; Morini M; Conte M; Di Cataldo A; Tondo A; D'Angelo P; Castellano A; Garaventa A; Lasorsa VA; Podestà M; Capasso M; Pezzolo A
Genes Chromosomes Cancer; 2020 May; 59(5):277-285. PubMed ID: 31756773
[TBL] [Abstract][Full Text] [Related]
10. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived organoids (PDOs) as a novel in vitro model for neuroblastoma tumours.
Fusco P; Parisatto B; Rampazzo E; Persano L; Frasson C; Di Meglio A; Leslz A; Santoro L; Cafferata B; Zin A; Cimetta E; Basso G; Esposito MR; Tonini GP
BMC Cancer; 2019 Oct; 19(1):970. PubMed ID: 31638925
[TBL] [Abstract][Full Text] [Related]
12. Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma.
Nguyen PHD; Ma S; Phua CZJ; Kaya NA; Lai HLH; Lim CJ; Lim JQ; Wasser M; Lai L; Tam WL; Lim TKH; Wan WK; Loh T; Leow WQ; Pang YH; Chan CY; Lee SY; Cheow PC; Toh HC; Ginhoux F; Iyer S; Kow AWC; Young Dan Y; Chung A; Bonney GK; Goh BKP; Albani S; Chow PKH; Zhai W; Chew V
Nat Commun; 2021 Jan; 12(1):227. PubMed ID: 33431814
[TBL] [Abstract][Full Text] [Related]
13. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).
Schleiermacher G; Michon J; Ribeiro A; Pierron G; Mosseri V; Rubie H; Munzer C; Bénard J; Auger N; Combaret V; Janoueix-Lerosey I; Pearson A; Tweddle DA; Bown N; Gerrard M; Wheeler K; Noguera R; Villamon E; Cañete A; Castel V; Marques B; de Lacerda A; Tonini GP; Mazzocco K; Defferrari R; de Bernardi B; di Cataldo A; van Roy N; Brichard B; Ladenstein R; Ambros I; Ambros P; Beiske K; Delattre O; Couturier J
Br J Cancer; 2011 Dec; 105(12):1940-8. PubMed ID: 22146831
[TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].
Su Y; Ma XL; Wang HM; Qin H; Qin MQ; Zhang FQ; Jin M; Zhang DW; Chen CH; Zeng Q; He LJ; Ni X
Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):796-801. PubMed ID: 32987457
[No Abstract] [Full Text] [Related]
15. Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.
Campbell K; Naranjo A; Hibbitts E; Gastier-Foster JM; Bagatell R; Irwin MS; Shimada H; Hogarty M; Park JR; DuBois SG
Eur J Cancer; 2020 Jul; 133():112-119. PubMed ID: 32492633
[TBL] [Abstract][Full Text] [Related]
16. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours.
Khalique L; Ayhan A; Weale ME; Jacobs IJ; Ramus SJ; Gayther SA
J Pathol; 2007 Feb; 211(3):286-95. PubMed ID: 17154249
[TBL] [Abstract][Full Text] [Related]
17. Results of neuroblastoma treatment in Lithuania: a single centre experience.
Juškaitė A; Tamulienė I; Rascon J
Acta Med Litu; 2017; 24(2):128-137. PubMed ID: 28845131
[TBL] [Abstract][Full Text] [Related]
18. Regression and progression in neuroblastoma. Does genetics predict tumour behaviour?
Ambros PF; Ambros IM; Strehl S; Bauer S; Luegmayr A; Kovar H; Ladenstein R; Fink FM; Horcher E; Printz G
Eur J Cancer; 1995; 31A(4):510-5. PubMed ID: 7576955
[TBL] [Abstract][Full Text] [Related]
19. Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy.
Gilson P; Merlin JL; Harlé A
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326534
[TBL] [Abstract][Full Text] [Related]
20. Neuroblastoma: the association of anatomical tumour site, molecular biology and patient outcomes.
Salim A; Raitio A; Pizer B; Mullassery D; Losty PD
ANZ J Surg; 2021 May; 91(5):1000-1004. PubMed ID: 33506998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
